Grifols (GRFS) Total Debt (2009 - 2026)
Grifols (GRFS) total debt from Dec 31, 2009 to Mar 31, 2026. The current Grifols (GRFS) total debt is $14B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Debt
Total Debt
Grifols (GRFS) Total Debt CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +2.76% |
| 3 Years TTM | +1.02% |
| 5 Years TTM | +7.13% |
| 10 Years TTM | +7.81% |
| All Time TTM | +26.54% |
Annual Total Debt change of Grifols (GRFS)
| Year | Total Debt | Change |
|---|---|---|
| 2025 | $14B | +7.56% |
| 2024 | $13B | -10.99% |
| 2023 | $15B | +5.31% |
| 2022 | $14B | +4.36% |
| 2021 | $14B | +29.63% |
| 2020 | $10B | -4.42% |
| 2019 | $11B | +22.54% |
| 2018 | $8.92B | +1.91% |
| 2017 | $8.75B | +30.70% |
| 2016 | $6.70B | -2.10% |
| 2015 | $6.84B | -2.27% |
| 2014 | $7B | +36.43% |
| 2013 | $5.13B | +3.80% |
| 2012 | $4.94B | -7.74% |
| 2011 | $5.36B | +238.74% |
| 2010 | $1.58B | +2.36% |
| 2009 | $1.55B | +58.22% |
| 2008 | $977M | +20.56% |
| 2007 | $810M | N/A |
Comparison Grifols (GRFS) total debt with competitors
Grifols (GRFS) total debt is $14.14B.
| Ticker | Name | Total Debt | Upside |
|---|---|---|---|
| MIRA | Mira Pharmaceuticals Inc | $114761.00 | -100.00% |
| NSRX | Nasus Pharma Ltd | $2.24M | -99.98% |
| MDCX | MDCorp | $6.00M | -99.96% |
| MDCXW | Medicus Pharma Ltd warrant | $6.00M | -99.96% |
| AMRN | Amarin Corp | $196.35M | -98.61% |
| SCLX | Scilex Holding Company | $547.71M | -96.13% |
| BIIB | Biogen Inc | $10.83B | -23.42% |
| OGN | Organon & Company | $12.09B | -14.50% |
| SNY | Sanofi | $54.88B | +288.02% |
| GSK | GSK Plc | $59.93B | +323.72% |
| BMY | Bristol-Myers Squibb Company | $66.37B | +369.27% |
| AZN | Astrazeneca plc | $66.63B | +371.09% |
| NVS | Novartis AG | $79.61B | +462.82% |
| PFE | Pfizer Inc | $117.21B | +728.72% |
| JNJ | Johnson & Johnson | $119.71B | +746.35% |
| NVO | Novo Nordisk | $356.16B | +2418.07% |